It Will Take a Decade to Vaccinate all Americans
------------------------------------------------
'We certainly are not at the numbers we wanted to be at the end of December,' he said. Dr Jha was more critical, warning that the vaccine rollout in the U.S. is following a familiar, disastrous pattern. 'We're repeating all the mistakes we made with PPEs and testing all over again,' he said in a separate Today show interview.


https://www.dailymail.co.uk/news/article-9097175/US-goal-vaccinate-80-...

It Will Take a Decade to Vaccinate all Americans
------------------------------------------------
'We certainly are not at the numbers we wanted to be at the end of December,' he said. Dr Jha was more critical, warning that the vaccine rollout in the U.S. is following a familiar, disastrous pattern. 'We're repeating all the mistakes we made with PPEs and testing all over again,' he said in a separate Today show interview.


https://www.dailymail.co.uk/news/article-9097175/US-goal-vaccinate-80-population-June-DECADE-complete-current-rate.html

Supermax price drop is so illogical - JP MORE GAIN

Keep CALM- SUPERMAN will return with a vengeance next month.
-----------------------------------------------------------

The PE for Supermax will fall to SINGLE digit for next quarter.

Normally, Supermax trade at 20 PE
.
FPE (Forward Price Earnings) is just about 3 for Supermax at current price.

Have you seen these scenarios happened and it last for few months?

Be calm, the share price will come back to its fair value soon.

Worst case Fair Valuation is RM10-00

Be Patient and Keep Calm Folks.

China's biggest GLOVE manufacturer is doing well today - up 5%.
------------------------------------
INTCO Mediical Technology Co Ltd
SHE: 300677
164.56 CNY +8.00 (5.11%)
28 Dec, 1:49 pm GMT+8 · Disclaimer

Be patient folks next month will see better sentiment on GLOVE counters particularly SUPERMAX.

@ Influenza19- Spot on Bro.

Covid 19 Fantasies.
--------------------
Gov bowing down to this so called recovery sector.
Fantasies of vaccine can settle it all.

Only 20% of vaccine coming the earliest this Feb.
Cannot create herd immunity but we are become complacent.

No need total lockdown, our country will crumble- economically.

But we are daydreamer, we believe vaccine can settle it all.

Yup, the whole world is lulled in to the belief that Vaccines will settle all.

Well said @Hazzy
-----------------
What is more certain ? Recovery stocks or glove stocks?

Glove prices have slowed down for you to buy now ( thanks for all the bad news ), whoever misses this should not even invest in shares anymore. It’s like money on the floor you don’t want to pick but prefer to pick a fight and hope for recovery stocks.

Even if glove prices stay put the dividend is a stable income than the FD you have in the ban. For me I think it will be better asset than a landed property to pass down. All the new companies jumping in will not dampen the fundamentals of glove biz especially against the top 4.

Trust them to do well in the next 30 years . They know how to make profits through scale
in cents. The new ones don’t know the difficulties and think its easy.

Health Care Workers Still Face Daunting Shortages of GLOVESand other PPEs.

By Andrew Jacobs of New York Times
Dec. 20, 2020

As Americans celebrate the rollout of a coronavirus vaccine, many of the doctors and nurses first in line for inoculation say a victory lap is premature. They fear that the optimism stirred by the vaccine will overshadow a crisis that has drawn scant public attention in recent months: the alarming shortage of personal protective equipment, or P.P.E., that has led frontline medical workers to ration their use of the disposable gloves, gowns and N95 respirator masks that reduce the spread of infection.

While others were building new factories SUPER MAX was busy building MOATS in USA & UK.
They are going to earn high margins and profits and sustainable as a result of this.
Yup SUper to the max.

Supermax: price trend reversal - JP More Gain
Author: JP More Gain | Publish date: Wed, 23 Dec 2020, 9:13 AM

You can see from the Supermax share price chart that it dropped from Rm 9.18 on 1st December to close at Rm 6.79 on 14th December, a drop of 35% in 2 weeks. This is due to JP Morgan’s downgrade all the glove stocks. Unfortunately, many investors believe in JP Morgan and sold their holdings aggressively. It is so ridiculous to mislead investors.

Supermaxxx will come lah- still in collection mode

Man man lai lah.

After Christmas will be flying to the moon

Short term TP 12-00 sap sap Sui lah.

Main ingredient now is Patience my dear Brothers.

Taiwan reports first local coronavirus infection since April.
----------------------------------------------

TAIPEI – Taiwan reported its first local coronavirus transmission today, ending 253 days of being virus-free in a major blow for an island that has been lauded for its pandemic response.

Health authorities said a woman in her 30s had tested positive for the coronavirus after coming into contact with a "foreign pilot" working for a Taiwanese airline who was a carrier. Published on 22 Dec 2020

Ya Lor Ah Pang- 3months of consolidation and it is time for GLOVES to start flying to the Moon again.

The new strain of cover coupled with the pandemic being out of controll will provide the much needed BOOST and upgrade all GLOVE counter, particularly SooooPerToooTheMaxxx.

Bye bye Recovery stocks as they will only recover in 2 years time, some will be in ICU.

Massive funds -retail and institutional will flow back to GLOVES.
--------------------------
Posted by pang72 > Dec 22, 2020 4:42 PM | Report Abuse

3mons consolidation is enough..

Time to fly

SUPERMAX Primed for listing in US- Nsadaq- Maybe in 3 years time.
-------------------------------------------
The plan already set in motion.

Factory to be set up in Delaware USA - Biden's hometown.

Whatever TP our IB wanna give now, let's just observe from time to time, maybe it will be adjusted as below:

RM9.88 for entering US market
RM10.05 for approval
RM11.88 for completion of factory construction
RM12.88 for start of production
RM13.88 for first dispatch of product
RM18.88 if Biden come home Delaware for opening ceremony hahahaha

This news will send the naysayers to the ZOO.

Suuuuper to the maxxxxx.

Latest on CNBC News- Just sharing ya.

The coronavirus spreading rapidly in Britain carries mutations that could mean children are as susceptible.
-----------------------------------------------

LONDON: A new variant of the coronavirus spreading rapidly in Britain carries mutations that could mean children are as susceptible to becoming infected with it as adults - unlike previous strains, scientists said on Monday (Dec 21).

Briefing reporters on the latest findings, scientists from the government's New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) who are tracking the variant said it had swiftly become the dominant strain in the south of Britain, and could soon do the same across the country.

"We now have high confidence that this variant does have a transmission advantage over other virus variants that are currently in the UK," said Peter Horby, a professor of emerging infectious diseases at Oxford University and chair of NERVTAG.

"There is a hint that it has a higher propensity to infect children," said Neil Ferguson, a professor and infectious disease epidemiologist at Imperial College London and also a member of NERVTAG.

Don't worry too much TP RM15-00 - no problem. Just buy and keep. No need to talk so much.
Gloves are still the most profitable sector left in BURSA- Super to the max.

TP of 15-00 is achievable for Supermax as NEW Variant of COVID 19 Surfaces in EUROPE
-----------------------------------

Others factors boosting SUPERMAX _

1- Venturing into US.

In an announcement to Bursa Malaysia, Supermx is venturing into the United States of America (USA) to manufacture Made-in-USA medical gloves and other personal protective equipment (PPE) as well as the building of a National Headquarters in the USA with an initial capital outlay of USD100m (RM405m). The group has incorporated Maxter Healthcare Incorporated with an issued and paid-up share capital of USD1. Subsequently, the paid-up share capital will be increased to USD100m (RM405m).

2- Beneficiary from gloves manufacturing and OBM distribution.

On new capacity, its Plant 12 comprises Block A and Block B, each consisting of 8 double former lines with 2.2b pieces each (total 4.4b pieces). As of now, for Block A, 3 new lines have started commissioning in end March 2020 on top of the 5 lines already in commercial production. For Block B, as all 8 lines were scheduled to be fully commissioned by 2H 2020, we expect the installed capacity (on full commercial production) to have risen by 13.4% to 26.2b pieces per annum by now.

3- Undemanding PER valuation & SGX listing

We continue to like Supermax because: (i) the stock is trading at an undemanding 8x FY21E EPS compared to expected explosive earnings growth of >100%, and (ii) its OBM model enables it to extract higher margin from distributor prices, compared to the OEM model at lower factory prices. Its inclusion in the FBMKLCI was effective today, coming in with a weight of 2.13% as expected. Other re-rating catalyst is the proposed dual listing on the Singapore Exchange (SGX).

.

Well said Bro. Many thanks for sharing. Yup see you at the Bonanza !
-----------------------------------

I am a staunch believer in the almighty power of rising earnings. I believe that Supermax earnings visibilities over the next few quarters are superb. The stock is so undervalued right now. Even if the demands for gloves taper, the stock will still be undervalued.

The stock price is like a dog on a leash. The dog can run up and down, left and right, but eventually, it comes back to the owner who holds the leash. In the stock market, that owner with a leash is the rising streams of earnings.

See you at the bonanza.

Interesting article on Supermax.

https://klse.i3investor.com/blogs/sts/2020-12-20-story-h1538310018-SUPERMAX_BONANZA_HOW_TO_TREAD_THE_MINEFIELD_TOWARDS_IT.jsp

Sad, this Biological warfare going to take years from the looks of it.
----------------------------------------------------------------
A sobering reminder to practice good hygiene standards.

The vaccination of millions of people may exert enormous pressure on the virus to become resistant to the immune response, setting back the global fight by years.

Glove will play a big part in this warfare.

EFFICACY of vaccines may be reduced significantly.
--------------------------------------------------

The mutated virus strain emerged in UK, South Africa and Europe, the Oxford expert said, this could cause the EFFICACY of vaccines to be reduced significantly.

So, how to control covid?

How to get the population to inject vaccines?

Keep safe Folks.

Wear mask n follow the SOPs.

@oohlala- Fully agree never, pull in humanity etc bullshit into analysis.
===============================================

Please don't pull in humanity etc bullshit into analysis. if that is the case, all big phamaceutical company should not earn what they are earning now, hospital and doctors should not charge the price they are charging now. in fact, glove price did not increase 10x. please refer to supermx press release, ex-factory price increased 3x while price to end user is about double from USD 90 to now USD 180-200. What makes a different is middle man being eliminated or their margin reduced.

A potent new strain of the virus detected in UK- Scary!
---------------------------------------------
European countries started banning flights coming from the UK on Sunday as government in London warned that a potent new strain of the virus was "out of control".

The moves come as around a third of England's population entered a Christmas lockdown and UK Health Secretary Matt Hancock warned that the new strain of virus was "out of control".

Detailed analysis on Supermax.


https://messenger.i3investor.com/res/msg/file/27922/2020/12/supermax_analysis_20201219153604.pdf

This is an interesting analysis on SUPER max- and not those half baked ones.


https://messenger.i3investor.com/res/msg/file/27922/2020/12/supermax_analysis_20201219153604.pdf

Spot on Calvin Tan
-------------------
calvintaneng he next question is what will be the NP margin once the demand spike by covid 19 is over and with the increase capacity and many newcomers joining the game?
19/12/2020 1:03 PM

Good question

My answers:

1) Many new comers are of little threat to established Medical Glove players

Unlike other consumer goods Medical Gloves are a Class on its own

No Surgeons/ Top Doctors will simply use "new gloves" from unproven, untested sources

THEY CANNOT TAKE THE RISK AS IT WILL BE TOO DANGEROUS TO THEMSELVES AS WELL AS THEIR PATIENTS

SO THEY WILL STILL STICK WITH PROVEN GLOVE COMPANY LIKE KOSSAN

2) WHY KOSSAN?

Because KOSSAN IS MORE LOYAL TO ITS FAITHFUL LONG TERM CUSTOMERS & DID NOT SIMPLY RAISE ASP PRICES

SO YOU CAN SEE KOSSAN PROFIT TRALED BEHIND OTHERS. NOW KOSSAN HAS PROVEN TO BE THE PRODUCT OF HIGHEST QUALITY WITH CLEANROOM GLOVES & CLEANROOM FACEMASKS

https://kossan.com.my/products/cleanroom/cleanroom.html

AND KOSSAN HAS FINALLY INCREASED ASP PRICES DUE TO ESCALATING COST OF MATERIAL
(RISING GLOVE CHEMICAL ALSO GOOD FOR LUXCHEM AS WELL)

SO KOSSAN SHOULD PLAY CATCH UP

3) WHAT ABOUT ALL THE NEW GLOVE WANNABEES?

TOPGLOVE BOSS ALREADY STATED THAT OUT OF 250 MEDICAL GLOVE COMPANIES 80% HAVE FAILED AND CLOSED SHOP - ONLY 50 REMAINING

SO CAN EXPECT 80% TO EVEN 95% OF NEW GLOVE WANNABEES TO FAIL LATER

THE 5% THAT DID NOT FAIL MIGHT SELL ITS OPERATIONS TO BIG GLOVE COMPANIES BECAUSE OF ECONOMY OF SCALE

APLI SOLD TO SUPERMAX

ADVENTA SOLD ITS MEDICAL GLOVE ARM TO TOP GLOVE

SO STAY INVESTED ONLY IN PROVEN GLOVE COMPANIES ESPECIALLY KOSSAN

Before You Rush For Covid-19 Vaccine, Remember This – You Can’t Sue Anyone If Suffer Any Serious Side Effects
------------------------------------------------------------------------------------------

December 18th, 2020 by financetwitter


DEC182020 Facebook Twitter Digg Pinterest Linked In
Moderna’s vaccine has become the second approved Coronavirus vaccine after Pfizer-BioNTech. The green light was granted by the U.S. Food and Drug Administration (FDA) advisory panel on Thursday (Dec 17). The 20-0 with one abstention decision, delivered by the FDA’s Vaccines and Related Biological Products Advisory Committee, came exactly 1-week after Pfizer got its approval.

Dr. Michael Kurilla, the only member who did not vote yes, explains his decision to abstain – “In the midst of a pandemic and with limited vaccine supply, a blanket statement for individuals for 18 years and older is just too broad. I’m not convinced for all of those age groups the benefits do actually outweigh the risk.”


Both Pfizer and Moderna’s vaccines are built based on genetic material called “mRNA” or messenger RNA vaccines – a new technology that’s never before been licensed in the U.S. These vaccines are not like a normal flu vaccine. However, Pfizer and Moderna have claimed effectiveness of 95% and 94.5% respectively. Both vaccines have side effects, of course.
Coronavirus - Covid-19 Vaccine Lawsuit
Now that there are two Covid-19 vaccines approved by the FDA, can you actually sue Pfizer or Moderna or even the government if you suffer severe side effects after taking the jab? Unfortunately, you will take the vaccine at your own risk. That means you CAN'T SUE the pharmaceutical companies, let alone the U.S. federal government in a U.S. court of law.

If you can’t sue Pfizer, Moderna or the U.S. government, common sense says you can’t sue your own non-U.S. government (assuming you do not reside in America). The reason you can’t sue the American drug makers is because the U.S. government has granted them “immunity from liability” – if something unintentionally goes wrong with their vaccines.

Well said Tony

Supermax will outshine the other 3 in 2021 due to higher EPS and with KLCI inclusion and subsequent SGX dual listing will command a better valuation with higher PE than now.
The current TPE are as follow:
-TG = 10.4 ( due to facing many issues lately)
-Harta = 42.0 ( funds favourite therefore overpriced)
-Supermax = 9.9 ( underestimated dark panther but will shine in 2021)
-Kossan = 12.2 ( right valuation )

Super to the max.

@moshi20's- fully agree with your comment posted in Supermax forum.

@sslee do you take into consideration that for manufacturing sector when certain cost is cover when the volume hit certain number, for every piece of products the factory produce the profit is much higher in comparison to the profit of the product before that? The higher profit margin could be due to the maximize of the production capacity also?

https://www.theedgemarkets.com/article/asp-nitrile-gloves-grow-30-octo...
The group's ASP for nitrile gloves in its fourth quarter ended Aug 31, 2020 (4QFY20) has more than doubled (103%) from 3QFY20, while on a year-to-year basis, it has increased by 114%. The ASP for nitrile gloves for FY20 as a whole is up 31% from FY19's.

The price of gloves didn't raise 10X as you claim to be. While the prices increase, the raw material cost also increases, is it not normal for manufacturing line to factor in this?

g @ Agjl- Fully agree with your comment posted in Supermax forum.


I find that our fren’s write out is full of flaws and with too simplistic assumptions...without taking into considerations of various variable and invariable factors in a business world....i would not go into it as if i m an expert. I will leave it to all of u to read and judge for yourself.
19/12/2020 11:45 AM

What pushes the share price up?

Author: JP Morganathan & MacCurry- lol. | Publish date: Fri, 18 Dec 2020

Among all the criteria such as dividend yield, cash flow, bank balance, net tangible assets (NTA), etc, the most powerful catalyst to push up the share price is profit growth prospect. Investors should not buy any stock that cannot report increasing profit. For example, currently almost all the property companies cannot report increasing profit because there is so much of oversupply of properties. There are so much of unsold properties in every town and city, although the company’s share prices are selling below their NTA.

Currently the Covid 19 pandemic is affecting almost all the listed companies except medical gloves stocks and medical products for the virus prevention. As a result, all the glove makers can easily increase their selling prices to make more and more profit.

Among all the glove stocks, Supermax has the best profit growth rate. Its price chart shows that it has gone up from 70 sen on 23rd March to close at Rm 6.90 yesterday. Supermax share price has increased nearly 10 times in the last 9 months due to surge in demand for gloves. Its EPS for the quarter ending September was 30.58 sen. Its previous quarter EPS was only 15.29 sen. Its profit has increased by 100%. Its profit for the next quarter ending December should be another new record high. The company will likely make the announcement in Mid-January.


Why investors are selling?

UK and US are starting to inject vaccines to their citizens to prevent the spread of the coronavirus. Many investors are selling because they believe the vaccine will reduce the demand for glove.

Another reason could be the big investors are purposely pushing down the price so that they can buy back at cheaper prices.

Serious long-term investors should know the current down trend is only temporary.

As long as the pandemic is not completely under control, the demand for gloves will continue to exceed supply and all the glove makers will continue to increase their selling prices to make more and more profit which should be reflected on their share prices.

We would like to suggest that if you did not sell earlier at higher prices, you should not sell now because I believe the price is very near its rock bottom. Moreover, Supermax will announce its next quarter result soon.

Our research shows that all the stocks in the other sectors cannot report better profit growth rate than glove stocks.

X

Very soon funds will shift from RECOVERY to GLOVES- as recovery stocks are being heavily sold down after surging without earnings support/backing.

The top pick will definitely SUPERMAX.

Powered by fantastic fundamentals and earnings potential.

BREAKING NEWS- SUPERMAX MAY GET UPGRADED TO- FTSE ALL WORLD INDEX

The STAR

Supermax may get upgraded to FTSE All World Index

Friday, 18 Dec 2020


Supermax will replace KLCC in the 30-stock KLCI as expected on Monday.

KUALA LUMPUR: Glove maker Supermax Corporation may get upgraded to FTSE All World Index from FTSE Global All Cap Index, acording to a news report.


THE BEST GROWTH STOCK IN BURSA.

FTSE All-World index

FTSE All-World index series is a stock market index that covers over 3,100 companies in 47 countries starting in 1986.It is calculated and published by the FTSE Group, a wholly owned subsidiary of the London Stock Exchange which originated as a joint venture between the Financial Times and the London Stock Exchange.

Goldberg BREAKING NEWS- SUPERMAX MAY GET UPGRADED TO- FTSE ALL WORLD INDEX

The STAR

Supermax may get upgraded to FTSE All World Index

BUSINESS
Friday, 18 Dec 2020


Supermax will replace KLCC in the 30-stock KLCI as expected on Monday.

KUALA LUMPUR: Glove maker Supermax Corporation may get upgraded to FTSE All World Index from FTSE Global All Cap Index, acording to a news report.


THE BEST GROWTH STOCK IN BURSA.

FTSE All-World index

FTSE All-World index series is a stock market index that covers over 3,100 companies in 47 countries starting in 1986.It is calculated and published by the FTSE Group, a wholly owned subsidiary of the London Stock Exchange which originated as a joint venture between the Financial Times and the London Stock Exchange.

History
This index has been calculated since 31 December 1986, originally as the FT-Actuaries World Indices.[3]

In 1995, Wood Mackenzie and Co., one of the original partners, sold its stake to Standard & Poor’s. The name of the index was changed to FT/S&P – Actuaries World Indices.

On 29 November 1999, FTSE International Limited acquired the stakes of Goldman Sachs and Standard & Poor’s. The name changed to the FTSE World Index series.

FTSE took exclusive rights to integrate the Baring Emerging Markets data series with its existing FTSE World Index series. This resulted in the creation of the FTSE All-World Index series on June 30, 2000.

On September 22, 2003, FTSE introduced enhancements to improve the coverage of mid cap stocks in the index and remove some smaller stocks. In line with these enhancements, FTSE also launched the FTSE Global Equity Index Series.

Global demand for gloves still on uptrend - global supply growth over the next two-to-three years would likely still not catch up with the increase in demand.
----------------------------------------------------------

CORPORATE NEWS
Thursday, 17 Dec 2020


PETALING JAYA: Global glove supplies are expected to grow between 15% and 25% annually over the next two to three years, on the back of higher usage and increased healthcare awareness.

Despite glovemakers’ aggressive expansion plans to capture the demand growth, CGS-CIMB Research said global supply growth over the next two-to-three years would likely still not catch up with the increase in demand.

“This assumes that there would be no supply disruptions due to unforeseen circumstances or delays in expansion plans, such as construction delays and raw material supply constraints.”

Hong Leong Investment Bank (HLIB) Research said requests from customers have NOT been decreasing or slowing down despite the positive inflow of vaccine news.


“Rather, the actual demand and supply for gloves would be dependent on when the vaccine is ready for mass immunisation. Hartalega Holdings Bhd shared that its pandemic allocation is taken up until October 2021, with spot orders remaining between 7% and 10% of total capacity.

“While Kossan Rubber Industries Bhd shared its current lead time is 15 months. Also, its major customers have locked in orders up till the end of 2021. Current spot orders for Kossan accounts for 15% of total volume, with the incoming capacity to be focused to supply spot orders.”

The research house said spot order average selling prices (ASP) are now above US$90 (RM365) per 1,000 pieces.

“Overall, management remains upbeat on its earnings prospects at least until the first half of 2021 with a possible softening in the second half of 2021.”

CGS-CIMB expected glovemakers to continue recording stronger quarters, backed by higher ASPs, increase in production capacity and higher economies of scale.

“Note that we have assumed ASP will continue on an uptrend to only the first quarter of 2021, hitting a conservative average of US$60 (RM243) per 1,000 pieces of gloves in that quarter.”

Additionally, CGS-CIMB said it is maintaining its “overweight” call on the glove sector.

We also have added calls on Supermax Corp Bhd and Kossan. We continue to like the sector given its strong earnings prospects, as it is a key beneficiary of the robust global glove demand owing to Covid-19.

“Potential re-rating catalysts include a surge in ASP and stronger-than-expected global glove demand. Downside risks include a sharp decline in ASP and lower-than-expected demand for gloves.”

HLIB is also maintaining its “overweight” call on the sector.

“Share price of glove players have seen weakness of late, largely due to vaccine development news flow. However, at current depressed valuations, we reckon that these negatives have been priced in.

“With the global Covid count still chalking new daily highs, we think the risk-to-reward ratio seems favourable at current levels.”

@ Taipan - on the 5th of Jan 2021.

The irrational exuberance on recovery play is starting to lose momentum- soon the Glove play will return with a vengeance.

The only sector that will shine in this pandemic.

Gloves fantastic fundamentals are improving by the day.

CIMB

GLOVEs to record stronger results in quarters ahead.

ASPs to continue on an uptrend until at least 2QCY21

500 days lead time.

Mah Sing’s glove production facility gearing up for roaring start
------------------------------------------------------------------
By Cheah Chor Sooi
15 hours ago
in Business, Mainstream, Top

MAH Sing Group Bhd is making significant headway in its proposed diversification plan into the gloves business with its targeted production being set for April 2021 to cater for the pent-up demand for gloves in both the domestic and export market.

A mere eight months into its initial planning date of August 2020, Mah Sing’s glove manufacturing plant which has a build-up of circa 228,800 sq ft is progressing according to schedule.

Its first six production lines will be on track to be operational as planned in 2Q 2021 followed by another six lines expected to be ready the following quarter (3Q 2021).

The 12 production lines are a part of Phase 1 of Mah Sing’s proposed diversification into gloves with a maximum capacity of 3.68 billion pieces per annum or 38,000 pieces per production line per hour.

The capital expenditure for Phase 1 of Mah Sing Healthcare’s glove business is estimated at RM160 mil. Mah Sing targets to roll out Phase 2 as an expansion plan when demand outstrips supply for Phase 1.

Phase 2 could accommodate another 12 new production lines and increase production capacity up to another 3.68 billion pieces of gloves per annum.

MS will gradually expand up to 100 production lines as part of its future expansion plans.

“The proposed glove business will strengthen our manufacturing division and is expected to generate sales as early as 2Q 2021,” Mah Sing CEO Datuk Ho Hon Sang pointed out.

“This will allow us to take advantage of the high spot price for gloves. This business will still see sustained, strong demand in the future, generating more recurring and steady income for the group.”

Ho further projected that Mah Sing plans to venture into other healthcare and medical device-related ventures if the opportunity arises.

“We may explore the possibility of listing our manufacturing division separately from the Group to further unlock its value in the future,” he envisaged.

According to Malaysian Rubber Glove Manufacturers Association (MARGMA), global demand for gloves is estimated to reach 360 billion pieces this year, an increase of 21.62% from 296 billion pieces in 2019.

Dec 16, 2020

Mah Sing Group mulls listing its manufacturing division — which includes its new rubber glove business — in Hong Kong.

Qualities of A Good Value Investor
--------------------------------
A good value-investor like Warren Buffet will take its position when a good fundamental stock is undervalue (insensibly sell-off by temporary weak sentiment or negative emotion). The big fund managers are collecting cheap ticket and will reallocate their portfolio in due time, pushing the share price up to reflect its fair value. The share market goes on rotational theme and don't expect that it stays in the same theme or momentum all the time, thus up and down, and irrational at times.

Exclusive-WHO vaccine scheme risks failure, leaving poor countries no COVID shots until 2024
---------------------------------------------------------
Dec 16, 2020

BRUSSELS (Reuters) - The global scheme to deliver COVID-19 vaccines to poorer countries faces a "very high" risk of failure, potentially leaving nations home to billions of people with no access to vaccines until as late as 2024, internal documents say.

The World Health Organization's COVAX programme is the main global scheme to vaccinate people in poor and middle income countries around the world against the coronavirus. It aims to deliver at least 2 billion vaccine doses by the end of 2021 to cover 20% of the most vulnerable people in 91 poor and middle-income countries, mostly in Africa, Asia and Latin America.

But in internal documents reviewed by Reuters, the scheme's promoters say the programme is struggling from a lack of funds, supply risks and complex contractual arrangements which could make it impossible to achieve its goals.

Vaccine deployment will generate demand of 18 billion pieces per annum
---------------------------------------------------------------------

KUALA LUMPUR : RHB Investment Bank Bhd said today Covid-19 vaccine deployment could be a new demand source for rubber gloves at up to 18 billion pieces a year assuming that 60% of the world’s population of 7.5 billion people will get the vaccine in two doses annually.

"As each contact with a person should lead to the usage of one pair of disposable gloves, a vaccine deployment will generate demand of 18 billion pieces per annum in the short term. If the vaccine protection period is only up to a year, this 18 billion pieces per annum demand will recur on an annual basis. This is equivalent to 6.8% of the 263 billion pieces per annum global gloves demand in 2019,” RHB analyst Alan Lim wrote in a note today.

Lim said RHB maintained its "overweight" call on the rubber glove sector as the long-term demand outlook for gloves remains extremely positive.

Here is a message from KYY especially to rr88.

Supermax’s 1st quarter ending September EPS 30.58 sen. Its EPS was 15.29 sen for its previous quarter, an increase of 100%. Based on Top Glove’s performance, Supermax’s profit for the next quarter ending December should be another new record profit. Most likely Supermax will announce its result in mid-January, that is about 5 weeks from now. Shareholders should wait patiently.

Breakingviews - Rubber-glove selloff gets out of hand
------------------------------------------------------
By Jennifer Hughes- Reuters . 16th December 2020

Rubber glove makers have rivalled Zoom Video Communications as a popular pandemic trade. A quadrupling in the shares of Malaysia’s Top Glove, the world’s largest producer, values it at $13 billion. Yet its shares have fallen one-.16th December 2020.third since its $19 billion October peak, leaving it trading at multiples far below even its pre-pandemic average. As investors rush to take profit on Covid-themed trades, they can leave value on the table.

Like Zoom, Top Glove peaked on Oct. 19 after Pfizer said it was close to filing for vaccine approval. Its cheap valuation suggests investors are treating the typically defensive sector like a cyclical one as vaccines arrive. But testing and inventory re-stocking will continue in the short-term and even beyond 2021, so it is plausible that industry growth will remain above its pre-2020 8% a year. Top Glove expects demand to rise 20% in its financial year to Aug. 31 and 25% the year after. A shift in countries’ use of protection could also lift demand. Before the pandemic China used fewer than 10 pairs of gloves per person a year, compared to over 100 in the United States, per Citigroup analysts.

Top Glove’s shares are trading at five times 2021 forecast earnings and a 2022 multiple of nine times – far below its 10-year average of 18 times. The company is working on a Hong Kong listing next year, which could raise more than $1 billion to fund expansion.


Investors may have moved on too soon.

And missed the opportunity to earn big bucks from this GEM.

Breakingviews - Rubber-glove selloff gets out of hand
------------------------------------------------------
By Jennifer Hughes- Reuters . 16th December 2020

Rubber glove makers have rivalled Zoom Video Communications as a popular pandemic trade. A quadrupling in the shares of Malaysia’s Top Glove, the world’s largest producer, values it at $13 billion. Yet its shares have fallen one-.16th December 2020.third since its $19 billion October peak, leaving it trading at multiples far below even its pre-pandemic average. As investors rush to take profit on Covid-themed trades, they can leave value on the table.

Like Zoom, Top Glove peaked on Oct. 19 after Pfizer said it was close to filing for vaccine approval. Its cheap valuation suggests investors are treating the typically defensive sector like a cyclical one as vaccines arrive. But testing and inventory re-stocking will continue in the short-term and even beyond 2021, so it is plausible that industry growth will remain above its pre-2020 8% a year. Top Glove expects demand to rise 20% in its financial year to Aug. 31 and 25% the year after. A shift in countries’ use of protection could also lift demand. Before the pandemic China used fewer than 10 pairs of gloves per person a year, compared to over 100 in the United States, per Citigroup analysts.

Top Glove’s shares are trading at five times 2021 forecast earnings and a 2022 multiple of nine times – far below its 10-year average of 18 times. The company is working on a Hong Kong listing next year, which could raise more than $1 billion to fund expansion.


Investors may have moved on too soon.

And missed the opportunity to earn big bucks from this GEM.

Breakingviews - Rubber-glove selloff gets out of hand
------------------------------------------------------
By Jennifer Hughes- Reuters . 16th December 2020

Rubber glove makers have rivalled Zoom Video Communications as a popular pandemic trade. A quadrupling in the shares of Malaysia’s Top Glove, the world’s largest producer, values it at $13 billion. Yet its shares have fallen one-.16th December 2020.third since its $19 billion October peak, leaving it trading at multiples far below even its pre-pandemic average. As investors rush to take profit on Covid-themed trades, they can leave value on the table.

Like Zoom, Top Glove peaked on Oct. 19 after Pfizer said it was close to filing for vaccine approval. Its cheap valuation suggests investors are treating the typically defensive sector like a cyclical one as vaccines arrive. But testing and inventory re-stocking will continue in the short-term and even beyond 2021, so it is plausible that industry growth will remain above its pre-2020 8% a year. Top Glove expects demand to rise 20% in its financial year to Aug. 31 and 25% the year after. A shift in countries’ use of protection could also lift demand. Before the pandemic China used fewer than 10 pairs of gloves per person a year, compared to over 100 in the United States, per Citigroup analysts.

Top Glove’s shares are trading at five times 2021 forecast earnings and a 2022 multiple of nine times – far below its 10-year average of 18 times. The company is working on a Hong Kong listing next year, which could raise more than $1 billion to fund expansion.


Investors may have moved on too soon.

And missed the opportunity to earn big bucks from this GEM.

Supermax won’t be the same post covid era. ASP may normalised, but I can guarantee it won’t go back to pre-covid era, share price won’t go back to pre-covid era neither.

By then they would’ve accumulated enough cash earnings to:

1.) diversify into other healthcare businesses.
2.) further expand their plants and equipments both locally and in UK.
3.) automate their glove manufacturing to compensate normalisation of ASP.
4.) earned the reputation to transform the now new customers into regular customers (new recurring earnings).
5.) higher dividend to distribute to shareholders.
6.) massive structural shift in the demand and usage of gloves post covid.
7.) Covid will be around for a long time despite the rollout of vaccines.

Supermax - A super stock worth accumulating.

IBs will be scrambling to short cover their short poistions in the next few days. This will drive up the share price.

Short covering refers to buying back borrowed securities in order to close out an open short position at a profit or loss. It requires purchasing the same security that was initially sold short, and handing back the shares initially borrowed for the short sale. This type of transaction is referred to as buy to cover.

Posted by SteadyT > Dec 16, 2020 10:07 AM | Report Abuse

Can I have the link please? Thanks

@Goldberg BREAKING NEWS= TP RM13.20

Latest TP Given BY CIMB on SUPERMAX- TARGET PRICE- RM13.20



https://klse.i3investor.com/m/blog/gloveharicut/2020-12-16-story-h1538225325-CIMB_GLOVEs_to_record_stronger_results_in_quarters_ahead_ASPs_to_contin.jsp